An announcement from Pyxis Oncology (PYXS) is now available.
Pyxis Oncology, Inc. has entered into a securities purchase agreement with certain investors for a private placement, aiming to raise around $50 million. The company plans to sell over 8.8 million shares and pre-funded warrants, with the closing set for February 29, 2024, and intends to use the proceeds for general corporate purposes and working capital. Additionally, they have committed to a registration rights agreement to enable the resale of these securities, ensuring they are registered with the SEC by a set deadline. The sale relies on an exemption from registration under the Securities Act, and the company has made relevant disclosures in a press release.
For a thorough assessment of PYXS stock, go to TipRanks’ Stock Analysis page.
